首页> 外文期刊>Current oncology >Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of The Ottawa Hospital Cancer Centre over 7 years
【24h】

Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of The Ottawa Hospital Cancer Centre over 7 years

机译:使用化学疗法和射频消融治疗结直肠癌转移:渥太华医院癌症中心7年回顾性回顾

获取原文

摘要

Background Almost 40% of people diagnosed with colorectal cancer will die from their disease, most with metastatic spread. When feasible, hepatic resection offers the greatest probability of cure for isolated liver metastases, but there are barriers to curative resection. Those barriers include the extent and distribution of lesions within the liver, extrahepatic disease, comorbidities, and age. Chemotherapy is often administered before or after resection with the intention of improving disease-free and overall survival. The timing of chemotherapy (adjuvant vs. neoadjuvant vs. perioperative) for patients undergoing potentially curative hepatic resection of metastasis of colorectal cancer origin is controversial. Methods Colorectal cancer patients with liver metastases resected at The Ottawa Hospital between January 1, 2003, and December 31, 2009, were identified, and their clinical records were retrospectively reviewed. Patients receiving intraoperative radiofrequency ablation (rfa) as part of their management were included. Factors associated with overall and diseasefree survival were evaluated. Results The 168 identified patients (57% men, 43% women) had a median age of 63 years (range: 31–84 years). After hepatectomy, 10% had positive resection margins. Intraoperative rfa was used in 25 patients (15%). Chemotherapy was administered in the neoadjuvant (19%), adjuvant (31%), or “perioperative” (both neoadjuvant and adjuvant, 50%) setting. Use or omission of intraoperative rfa was not associated with a difference in overall survival (hazard ratio: 0.99; 95% confidence interval: 0.53 to 1.84; p = 0.97). Conclusions Compared with patients who did not receive chemotherapy, those who received chemotherapy, regardless of timing, experienced improved overall survival and disease-free survival. Use of rfa where required as an adjunct to hepatic resection appears to be effective and is not associated with worse overall survival.
机译:背景资料大约40%的被诊断为大肠癌的人会死于疾病,大部分会转移。在可行的情况下,肝切除术可为孤立的肝转移提供最大的治愈机会,但治愈性切除术存在障碍。这些障碍包括肝脏内病变的程度和分布,肝外疾病,合并症和年龄。化疗通常在切除术之前或之后进行,目的是改善无病生存期和总体生存期。对于可能进行治愈性结直肠癌起源转移性肝切除术的患者,化疗的时机(辅助,新辅助,围手术期)存在争议。方法对2003年1月1日至2009年12月31日在渥太华医院手术切除的结直肠癌肝转移患者进行回顾性分析。纳入接受术中射频消融(rfa)作为治疗一部分的患者。评估与总体生存和无病生存相关的因素。结果168例确定的患者(男性57%,女性43%)的中位年龄为63岁(范围:31-84岁)。肝切除术后,有10%的切除切缘阳性。术中射频消融术用于25例患者(占15%)。化学疗法以新辅助剂(19%),辅助剂(31%)或“围手术期”(新辅助剂和辅助剂,分别为50%)的方式给予。术中使用或不使用rfa与总生存期无差异(危险比:0.99; 95%置信区间:0.53至1.84; p = 0.97)。结论与未接受化疗的患者相比,接受化疗的患者无论时机如何,其总生存期和无病生存期均得到改善。必要时使用rfa作为肝切除的辅助措施似乎是有效的,并且与较差的总生存期无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号